- /
- Supported exchanges
- / V
- / RKV.V
Rakovina Therapeutics Inc (RKV V) stock market data APIs
Rakovina Therapeutics Inc Financial Data Overview
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Additionally, it signed a letter of intent with NanoPalm Ltd. to form a joint venture to co-develop novel small-molecule oncology therapeutics. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Rakovina Therapeutics Inc data using free add-ons & libraries
Get Rakovina Therapeutics Inc Fundamental Data
Rakovina Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -7 750 175
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Rakovina Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Rakovina Therapeutics Inc News
New
Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7J0), a biopharmaceutical company advancing next-g...
Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 – World’s Premier Cancer Research Forum
VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artifici...
Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million
Proposed $1.0 Million Convertible Debenture and Warrant Financing and Concurrent Common Share Private Placement Up to $1.0 Million Intended to Support Near-Term Operations VANCOUVER, British Colu...
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent lat...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.